8-K: Viracta Therapeutics Announces Positive Clinical Trial Results and First Quarter 2024 Financials

Viracta Therapeutics reported positive topline results from its Phase 2 NAVAL-1 trial for Nana-val in relapsed or refractory EBV+ peripheral T-cell lymphoma and provided a business update along with first quarter 2024 financial results.

Summary

• Viracta Therapeutics announced its first quarter 2024 financial results and provided an update on its clinical programs.
• The company presented positive topline results from Stage 1 of the Phase 2 NAVAL-1 trial for Nana-val in patients with relapsed or refractory Epstein-Barr virus-positive peripheral T-cell lymphoma.
• The NAVAL-1 trial showed a 50% objective response rate and a 20% complete response rate in the intent-to-treat population for the Nana-val arm.
• The company plans to engage with the FDA in mid-2024 to discuss an accelerated approval pathway for Nana-val.
• Viracta is also progressing its Phase 1b/2 study of Nana-val in patients with advanced EBV+ solid tumors and expects to determine the recommended Phase 2 dose in the second half of 2024.
• The company's cash position was approximately $39.6 million as of March 31, 2024, which is expected to fund operations into late Q1 2025.
• Research and development expenses were approximately $10.0 million for the first quarter of 2024, compared to $7.6 million for the same period in 2023.
• The net loss for the quarter was approximately $9.1 million, or $0.23 per share, compared to a net loss of $12.2 million, or $0.32 per share, for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results and a clear path towards regulatory approval, along with a solid cash position. The improved financial results and strategic engagement with regulatory agencies contribute to a positive outlook.

Positives

• The NAVAL-1 trial showed a strong signal of efficacy for Nana-val, with response rates exceeding those of nanatinostat monotherapy.
• The safety profile of Nana-val was generally well-tolerated and consistent with previous studies.
• Engagement with the PMDA in Japan allows for direct enrollment of patients into the NAVAL-1 trial, streamlining the process.
• The company's cash runway extends into late Q1 2025, providing financial stability for ongoing operations.
• The net loss per share improved from $0.32 to $0.23 year-over-year.

Negatives

• Research and development expenses increased to approximately $10.0 million for the quarter, up from $7.6 million in the same period last year.
• The company reported a net loss of approximately $9.1 million for the quarter.
• The company is still in the clinical trial phase and has not yet achieved commercialization.

Risks

• The company's ability to successfully enroll patients in and complete its ongoing and planned clinical trials is a risk.
• There is a risk that previous preclinical and clinical results may not be predictive of future clinical results.
• The company's ability to manufacture or supply nanatinostat, valganciclovir, and pembrolizumab for clinical testing is a risk.
• The company's estimates regarding its ability to fund ongoing operations into 2025 may be impacted by unforeseen circumstances.
• The company may need additional financing in the future.

Future Outlook

The company expects to engage with the FDA in mid-2024 to align on requirements for accelerated approval of Nana-val and plans to present additional data from the NAVAL-1 trial in the third quarter of 2024. They also anticipate determining the recommended Phase 2 dose for the Phase 1b/2 study of Nana-val in advanced EBV+ solid tumors in the second half of 2024 and expect to fund operations into late Q1 2025.

Management Comments

• Our near-term goal is to address the high unmet medical needs of patients living with relapsed or refractory EBV-positive PTCL by advancing Nana-val through regulatory approval as quickly as possible, said Mark Rothera, President and Chief Executive Officer of Viracta.
• The observed objective and complete response rates of Nana-val far exceeded the nanatinostat monotherapy arm, further validating the combined mechanism of action of Nana-val treatment.

Industry Context

The announcement is significant in the context of the oncology industry, particularly for the treatment of rare and aggressive lymphomas. The positive results for Nana-val in EBV+ PTCL address a high unmet medical need, as there is currently no approved targeted treatment for this specific condition. The company's engagement with both the FDA and PMDA highlights its global approach to regulatory approvals.

Comparison to Industry Standards

• The reported objective response rate (ORR) of 50% and complete response rate (CRR) of 20% in the intent-to-treat population for the Nana-val arm in the NAVAL-1 trial are promising when compared to historical outcomes for relapsed or refractory PTCL.
• Traditional treatments for R/R PTCL often have lower response rates and shorter durations of response, with median progression-free survival and median overall survival times reported to be 3.7 and 6.5 months, respectively.
• While specific comparisons to other targeted therapies for EBV+ lymphomas are limited due to the novelty of the approach, the results suggest a potential improvement over existing treatment options.
• Companies like Seagen and ADC Therapeutics are developing antibody-drug conjugates for lymphomas, but these are not specifically targeted at EBV+ disease, making Viracta's approach unique.
• The engagement with PMDA for direct enrollment in Japan is a positive step, as it allows for a more efficient trial process compared to the traditional approach of conducting separate Phase 1 studies in Japan.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results and the potential for accelerated approval.
• Patients with relapsed or refractory EBV+ lymphomas may benefit from the development of Nana-val as a new treatment option.
• Employees may be motivated by the progress of the company's clinical programs and the potential for commercial success.
• The company's financial stability and cash runway provide confidence to creditors and suppliers.

Next Steps

• Engage with the U.S. Food and Drug Administration (FDA) in mid-2024 to align on requirements for accelerated approval.
• Enroll patients into the post-Phase 2 expansion cohort to support potential accelerated approval.
• Present Stage 1 + Stage 2 data (n=21) in the R/R EBV+ PTCL cohort in patients treated with Nana-val in the third quarter of 2024.
• Report Stage 1 data from patients with R/R EBV+ diffuse large B-cell lymphoma (DLBCL) and R/R EBV+ post-transplant lymphoproliferative disorder (PTLD) by year-end 2024.
• Determine the recommended Phase 2 dose (RP2D) in the second half of 2024 for the Phase 1b/2 trial of Nana-val in patients with recurrent/metastatic (R/M) EBV+ nasopharyngeal carcinoma (NPC) and other advanced EBV+ solid tumors.
• Initiate a dose-optimization cohort to confirm the RP2D as part of the study's Phase 2 expansion by year-end 2024.
• Engage with the PMDA in the second half of 2024 to align on a potential approval pathway for Nana-val in R/R EBV+PTCL.

Key Dates

Keywords

Nana-val, Epstein-Barr virus, EBV, lymphoma, peripheral T-cell lymphoma, PTCL, clinical trial, nanatinostat, valganciclovir, FDA, PMDA, oncology, cancer, Phase 2, Phase 1b/2